1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1–134.
2. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125(6):2140–2145.
3. Niederman MS, Mandell LA, Anzueto A, et al; American Thoracic Society. Guidelines for the management of adults with community- acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7): 1730–1754.
4. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27–S72.
5. BTS Pneumonia Guidelines Committee. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults-2004 Update. Available from: 
6. Woodhead M, Blasi F, Ewig S, et al; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26(6):1138–1180.
7. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy. 2004;50 Suppl 1:3–10.
8. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003). Diagn Microbiol Infect Dis. 2006;56(1):69–74.
9. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2003;46(4):285–289.
10. Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract. 2006;60(12):1662–1672.
11. Wyeth Pharmaceuticals. Tygacil (Package Insert). Philadelphia (PA): Wyeth Pharmaceuticals; 2010.
12. Breedt J, Teras J, Gardovskis J, et al; Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49(11):4658–4666.
13. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9(5):251–261.
14. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005; 41 Suppl 5:S354–S367.
15. Bergallo C, Jasovich A, Teglia O, et al; 308 Study Group. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63(1):52–61.
16. Tanaseanu C, Milutinovic S, Calistru PI, et al; 313 Study Group. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med. 2009;9:44.
17. Tanaseanu C, Bergallo C, Teglia O, et al; 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61(3):329–338.
18. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, appli- cations, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232–260.
19. Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother. 1992;29(3):245–277.
20. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev. 1992;5(4):387–399.
21. Bergeron J, Ammirati M, Danley D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996;40(9):2226–2228.
22. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother. 1994;38(7):1658–1660.
23. Tally FT, Ellestad GA, Testa RT. Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother. 1995;35(4):449–452.
24. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy. 2000;20(9 Pt 2):219S–223S.
25. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a com- parative review with the tetracyclines. Drugs. 2004;64(1):63–88.
26. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother. 2003;47(3):972–978.
27. Hornsey M, Ellington MJ, Doumith M, Scott G, Livermore DM, Woodford N. Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. Int J Antimicrob Agents. 2010;35(5):478–481.
28. Hornsey M, Ellington MJ, Doumith M, Hudson S, Livermore DM, Woodford N. Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY -HasF efflux system also active against ciprofloxacin and cefpirome. J Antimicrob Chemother. 2010;65(3): 479–482.
29. Wieczorek P, Sacha P, Hauschild T, Zórawski M, Krawczyk M, Trynisze- wska E. Multidrug resistant Acinetobacter baumannii–the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol. 2008;46(3):257–267.
30. Rajendran R, Quinn RF, Murray C, McCulloch E, Williams C, Ramage G. Efflux pumps may play a role in tigecycline resistance in Burkholderia species. Int J Antimicrob Agents. 2010;36(2):151–154.
31. Hentschke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline. Antimicrob Agents Chemother. 2010;54(6): 2720–2723.
32. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 8th ed. Wayne (PA): CLSI; 2009.
33. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Performance Standards for Antimicrobial Susceptibility Testing–19th Informational Supplement. Wayne (PA): CLSI; 2009.
34. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 7th ed. Wayne (PA): CLSI; 2007.
35. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005;52(3):181–186.
36. Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected glob- ally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis. 2010;67(1):78–86.
37. Garrison MW, Nuemiller JJ. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Int J Antimicrob Agents. 2007;29(2):191–196.
38. Yamamoto T, Nishiyama A, Takano T, et al. Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance. J Infect Chemother. 2010;16(4): 225–254.
39. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–2004 influenza season. Emerg Infect Dis. 2006;12(6):894–899.
40. Napolitano LM, Brunsvold ME, Reddy RC, Hyzy RC. Community- acquired methicillin-resistant Staphylococcus aureus pneumonia and ARDS: 1-year follow-up. Chest. 2009;136(5):1407–1412.
41. Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis. 2008;60(4):433–436.
42. Smith K, Gould KA, Ramage G, Gemmell CG, Hinds J, Lang S. Influence of tigecycline on expression of virulence factors in biofilm- associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(1):380–387.
43. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ; CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47(6):1875–1881.
44. Ko KS, Song JH, Lee MY, et al. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn Microbiol Infect Dis. 2006;55(4):337–341.
45. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother. 2006;50(10): 3479–3484.
46. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther. 2008;30(11):2040–2050.
47. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteri- aceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect. 2007;55(1):49–57.
48. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis. 2005; 41 Suppl 5:S315–S332.
49. El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003;167(12):1650–1654.
50. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopris- tin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 2001;45(9):2604–2608.
51. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents. 2000;16(1):61–63.
52. Wyeth Pharmaceuticals. Response Letter for Tigecycline Inquiry Regarding Legionella pneumophilia in vitro Data (Data on File). Philadelphia (PA): Wyeth Pharmaceuticals; 2010.
53. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2003;47(2):533–540.
54. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):220–229.
55. Rubino CM, Forrest A, Bhavnani SM, et al. Tigecycline population pharmacokinetics in patients with community-or hospital- acquired pneumonia. Antimicrob Agents Chemother. 2010;54(12): 5180–5186.
56. Darling IM, Cirincione BB, Owen JS. Noncompartmental pharmacokinetics of tigecycline in Phase 3 studies of patients with complicated skin and skin-structure and intra-abdominal infections. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; December 16–19, 2005; Washington, DC.
57. Macgowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008;62 Suppl 1:i11–i16.